argenx (NASDAQ:ARGX) Stock Price Expected to Rise, HC Wainwright Analyst Says

argenx (NASDAQ:ARGX - Get Free Report) had its price target increased by investment analysts at HC Wainwright from $717.00 to $720.00 in a research report issued on Friday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. HC Wainwright's target price indicates a potential upside of 15.90% from the company's current price. HC Wainwright also issued estimates for argenx's Q3 2025 earnings at $1.68 EPS and FY2025 earnings at $6.50 EPS.

Other equities research analysts also recently issued research reports about the stock. JMP Securities increased their price objective on shares of argenx from $606.00 to $696.00 and gave the stock a "market outperform" rating in a research report on Tuesday, January 14th. Guggenheim lifted their price target on argenx from $585.00 to $665.00 and gave the company a "buy" rating in a research note on Friday, November 1st. Piper Sandler upped their price objective on argenx from $620.00 to $725.00 and gave the stock an "overweight" rating in a research report on Tuesday, January 7th. Evercore ISI lifted their target price on argenx from $675.00 to $706.00 and gave the company an "outperform" rating in a research report on Thursday, November 21st. Finally, Deutsche Bank Aktiengesellschaft cut shares of argenx from a "hold" rating to a "sell" rating in a research note on Friday, January 17th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $662.83.

Remove Ads

argenx Price Performance

Shares of ARGX stock traded down $1.36 during trading hours on Friday, reaching $621.25. The company had a trading volume of 285,887 shares, compared to its average volume of 273,951. argenx has a 1-year low of $349.86 and a 1-year high of $678.21. The company has a 50 day moving average of $642.51 and a 200 day moving average of $591.91. The firm has a market cap of $37.75 billion, a price-to-earnings ratio of -705.97 and a beta of 0.58.

argenx (NASDAQ:ARGX - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.60. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The company had revenue of $761.22 million during the quarter, compared to the consensus estimate of $678.52 million. As a group, sell-side analysts forecast that argenx will post 3.13 EPS for the current fiscal year.

Institutional Investors Weigh In On argenx

A number of large investors have recently added to or reduced their stakes in the stock. US Bancorp DE increased its position in shares of argenx by 7.8% in the third quarter. US Bancorp DE now owns 4,350 shares of the company's stock worth $2,358,000 after purchasing an additional 316 shares during the period. Janney Montgomery Scott LLC lifted its holdings in shares of argenx by 201.2% during the 3rd quarter. Janney Montgomery Scott LLC now owns 2,072 shares of the company's stock worth $1,123,000 after acquiring an additional 1,384 shares during the period. Nvwm LLC bought a new position in argenx in the third quarter valued at approximately $533,000. Keudell Morrison Wealth Management bought a new position in argenx in the third quarter valued at approximately $207,000. Finally, Assetmark Inc. raised its position in argenx by 8.3% during the third quarter. Assetmark Inc. now owns 7,769 shares of the company's stock valued at $4,211,000 after purchasing an additional 598 shares in the last quarter. Institutional investors and hedge funds own 60.32% of the company's stock.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.